Physician profile
Jason P Gray
NPI 1730387283
$2,703.28
in general payments reported to CMS, 2019-2025
28 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $95.38 · 2021: $613 · 2022: $267 · 2023: $577 · 2024: $372 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $564.43 | 2019-2025 | Clareon, Hydrus Microstent, Unity |
| Regeneron Healthcare Solutions, INC. | $362.94 | 2019-2025 | Eylea Hd, Eylea |
| Lensar, INC. | $256.61 | 2021 | |
| Allergan, INC. | $157.44 | 2019-2022 | |
| Treace Medical Concepts, INC. | $150.35 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $149.54 | 2019-2024 | Tecnis Simplicity |
| Rxsight INC | $142.30 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Glaukos Corporation | $83.75 | 2023-2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $75.20 | 2019-2021 | |
| Harrow Eye, LLC | $68.80 | 2025 | Vevye, Triesence |
| Mallinckrodt Hospital Products INC. | $63.90 | 2024-2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $62.97 | 2019-2021 | |
| Dompe US, INC. | $59.49 | 2024-2025 | Oxervate |
| Genentech USA, INC. | $52.11 | 2023-2025 | Vabysmo |
| Abbvie INC. | $44.08 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $43.66 | 2019 | |
| Biotissue Holdings INC. | $43.64 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $43.40 | 2019-2023 | |
| Oyster Point Pharma, INC. | $42.27 | 2022-2023 | Tyrvaya |
| Astellas Pharma US INC | $41.69 | 2023-2025 | Izervay |
| Astellas Pharma Global Development | $34.48 | 2024 | Izervay |
| Shire North American Group INC | $31.48 | 2019 | |
| Horizon Therapeutics Plc | $26.37 | 2022-2023 | Tepezza |
| Coopervision INC. | $25.65 | 2022 | |
| Amgen INC. | $21.33 | 2024 | Tepezza |
| Carl Zeiss Meditec, INC. | $20.31 | 2019 | |
| Bausch & Lomb Americas INC. | $19.06 | 2024 | Miebo, Xiidra |
| Eyevance Pharmaceuticals LLC | $16.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.